Clinical outcomes of FOLFIRINOX and gemcitabine–nab paclitaxel for metastatic pancreatic cancer in the real world setting

• F. Franco ^[1] ; J.C. Camara ^[2] ; J. I. Martín-Valadés ^[3] ; A. López-Alfonso ^[4] ; D. Marrupe ^[5] ; D. Gutiérrez-Abad ^[6] ; B. Martínez-Amores ^[7] ; A. León ^[3] ; I. Juez ^[6] ; M. Pérez ^[4] ; A. Royuela ^[1] ; A. Ruiz-Casado ^[1]
  1. [1] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  2. [2] Fundación Hospital Alcorcón

     Fundación Hospital Alcorcón

     Alcorcón, España

     
  3. [3] Fundación Jiménez Díaz

     Fundación Jiménez Díaz

     Madrid, España

     
  4. [4] Hospital Infanta Leonor

     Hospital Infanta Leonor

     Madrid, España

     
  5. [5] Hospital de Móstoles

     Hospital de Móstoles

     Móstoles, España

     
  6. [6] Hospital de Fuenlabrada

     Hospital de Fuenlabrada

     Fuenlabrada, España

     
  7. [7] Hospital Universitario Rey Juan Carlos

     Hospital Universitario Rey Juan Carlos

     Móstoles, España

     

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 4, 2021, págs. 812-819
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background/objectives The incidence of pancreatic cancer is increasing in developed countries. The incorporation of new therapies, to the first-line treatment of patients with good performance status led to better survival in clinical trials. However, there is a wide variability in their use and some concerns about the treatment of elderly patients who were not included in the clinical trials.

    Methods This is a retrospective multicenter study. Data from consecutive patients diagnosed with metastatic pancreatic cancer (mPC) treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) were analysed to evaluate efficacy (overall survival—OS) and toxicity.

    Results A total of 119 patients were included. 49.6% were treated with FFX and 50.4% with GNP in first-line. The median OS was 12 months with no statistically significant differences between both regimens (12.7 m for FFX vs 10.2 m for GnP). Elevated Ca 19.9 levels and neutrophil–lymphocyte ratio (NLR) increased the risk of death. Patients who received both regimens in first/second line had a median OS longer than 15 months whichever the sequence. 32 patients (27%) were older than 70-y. 54% patients received a second-line treatment, 56% in the FFX group and 44% in the GnP group. The median OS for patients older than 70 was 9.5 m versus 12.3 m for patients younger than 70. Progression of the disease was the cause of death in 67.6% of the patients.

    Conclusions In our setting, the use of FFX and GnP for treating mPC is quite similar, but superiority could not be demonstrated for any of the schemes in the first line. OS was determined by basal levels of Ca 19.9 and NLR. Patients receiving both regimens in first/second line whichever the sequence, exhibited the best survival rates. In our series, elderly patients had poorer survival rates.